Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat
In conclusion, Empa therapy protected heart and kidney against CRS injury.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Brain Cancers | Cardiology | Cardiomyopathy | Chronic Kidney Disease | Dilated Cardiomyopathy | Drugs & Pharmacology | Empagliflozin | Heart | Heart Failure | Jardiance | Mitochondrial Disease | Nephrectomy | Neurology | Study | Urology & Nephrology